NCT07613281尚未招募不适用
A Prospective, Non-Randomized, Multi-Center, Two-Arm Study Evaluating the Serene Sleep Palatal Implant System
Serene Sleep, Inc.2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 26
- 试验地点
- 2
研究概览
简要总结
This clinical investigation is a prospective, non-randomized, parallel-group clinical investigation conducted at two (2) investigative sites. Study participants will be assigned to one of two study groups, snoring and obstructive sleep apnea, in a parallel manner based on predefined eligibility criteria.
The study aims to evaluate and compare outcomes between the two groups under investigation. The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
The design allows for the concurrent enrollment and follow-up of participants in both arms, enabling direct observation of differences in safety across the groups over time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A potential participant must meet ALL the following criteria to be enrolled into this study:
- •Participant is ≥18 years of age.
- •Participant has Body Mass Index (BMI) less than or equal to 30 kg/m²
- •Participant has a tonsil grade less than or equal to 2
- •Participant has a Friedman Tongue Position (FTP) I or II
- •Participant is able to provide voluntary written informed consent.
- •For a snoring participant to be selected for the study:
- •Confirmed identification of palatal snoring
- •Investigators will utilize standard of care clinical assessment methods to confirm the presence of palatal snoring prior to enrollment. These methods may include patient-reported history, physical examination of the upper airway, and auscultation or audio recordings.
- •Confirmed elimination of potential sleep apnea diagnosis
- •If the evaluating doctor suspects that the participant may be experiencing OSA, investigators will utilize standard of care clinical assessment methods to confirm OSA.
- •A resulting AHI <5 would classify the participant as an eligible snoring subject
- •For an OSA participant to be selected for study:
- •Confirmed identification of apnea caused by palatal collapse
- •Investigators should be able to make this identification through intraoral evaluation in accordance with their standard of care
- •Confirmed mild-to-moderate classification of OSA
- •If the evaluating investigator knows or suspects that the participant may be experiencing OSA, standard of care diagnostic methods will be used as confirmation.
- •A resulting AHI between 5 and 30 would classify the participant as an eligible OSA subject.
排除标准
- •A potential participant will be excluded from enrollment if ANY of the following conditions apply:
- •A record of allergic reaction to polyethylene terephthalate (PET) / polyester
- •An overly sensitive gag reflex
- •Septal deviation or nasal obstruction
- •Nasal polyps
- •Severe seasonal allergies
- •Soft palate length insufficient to accommodate implants
- •Prior Diagnosis of Lingual tonsil hypertrophy
- •Hypopharyngeal obstruction
- •Previous pharyngeal surgery
- •Previous upper respiratory tract cancer or radiation therapy
- •Active respiratory tract infection
- •Dysphagia or speech disorder
- •Neurologic disorder
- •Unstable psychiatric disorder
- •Pregnant or breastfeeding
- •History of falling asleep driving or Motor Vehicle Accident (MVA) due to sleepiness
- •Clinical Presentation that suggests Severe OSAHS (ESS >20, participant report of choking or gasping during sleep, etc.)
- •Marfan's Syndrome, Ehler-Danlos syndromes or other disorders of connective tissue and/or muscular tissue
- •Other sleep disorders
- •Other significant craniofacial anomaly
- •Participant is participating in any of the following:
- •A study with the same or similar primary endpoint
- •Any study in which the investigator determines may interfere with the results of this study
- •Participant is unwilling to complete all study related assessments and follow-up visits
- •Participant is unwilling or unable to abstain from all alcohol consumption for 24 hours leading up to the intake sleep study
- •Participant is unwilling or unable to abstain from all smoking, vaping, and/or oral tobacco products for 48 hours following the procedure
- •Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
3 期
Effect of Eluxadoline in Comparison to Mebeverine for Treatment of Patients With Diarrhoea-Predominant Irritable Bowel SyndromeCTRI/2024/02/062593Sun Pharmaceutical Industries Limited356
招募中
3 期
Effectiveness and safety study of Inj. Pembrolizumab in patients with Lung cancerCTRI/2025/07/090716Hetero Biopharma Limited228
尚未招募
2 期
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerNCT07318883Shanghai Henlius Biotech720
招募中
2 期
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary AldosteronismPrimary AldosteronismNCT07470983Shandong Suncadia Medicine Co., Ltd.60
招募中
不适用
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT07285382wanghaibo120